Omnicare Faces Probe Over Possible FCA Offenses, Kickbacks

Law360, New York (April 24, 2013, 5:05 PM EDT) -- Omnicare Inc. on Wednesday said the U.S. Department of Justice is investigating whether the pharmaceutical giant has violated the False Claims Act or federal anti-kickback law in connection with the company’s consumer collections practices.

In a filing with the U.S. Securities and Exchange Commission, Omnicare also disclosed that the DOJ is investigating possible FCA and anti-kickback violations with respect to agreements the company had with Abbott Laboratories, the manufacturer of the anti-seizure drug Depakote.

Omnicare said it is cooperating with both investigations and “believes that it...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.